Matarin Capital Management LLC Decreased Its Stake in Enanta Pharmaceuticals INC (ENTA) by $2.53 Billion as Shares Declined

During 2018 Q2 the big money sentiment decreased to 1.5. That’s change of 0.16, from 2018Q1’s 1.66. 16 investors sold all, 46 reduced holdings as ENTA ratio turned negative. 59 rose holdings while 34 funds amassed holdings. Funds hold 14.64 million shares thus 3.25% more from 2018Q1’s 14.18 million shares. 4,321 were accumulated by Element Cap Mngmt Ltd Limited Liability Company. Daiwa Grp Incorporated holds 0% or 105 shs in its capital. Meeder Asset Management holds 0% or 2,317 shs in its capital. Zurcher Kantonalbank (Zurich Cantonalbank) reported 549 shs or 0% of all its holdings. State Of Wisconsin Investment Board invested 0.01% of its capital in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Texas Permanent School Fund invested in 0.01% or 9,327 shs. Gsa Cap Prtn Limited Liability Partnership owns 0.14% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 24,400 shs. 20,082 are owned by National Bank & Trust Of Montreal Can. Sei Investments Co reported 2,268 shs. Acadian Asset Mngmt Ltd Company holds 381,729 shs or 0.19% of its capital. Gotham Asset Limited Liability Corp has invested 0.03% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Manufacturers Life Co The, Ontario – Canada-based fund reported 12,460 shs. Sg Americas Lc invested in 0% or 1,795 shs. Caxton Assocs LP accumulated 3,311 shs or 0.02% of the stock. Amer Century Cos Incorporated owns 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 32,428 shs.

ENTA had 5 sales and 0 insider purchases since June 11, 2018. This’s net activity of $6.27 million. Luly Jay R. sold $4.38 million worth of stock or 35,000 shs. MELLETT PAUL J also sold $1.81 million worth of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shs.

In Enanta Pharmaceuticals Inc. (ENTA) was reduced the holdings held by Matarin Capital Management Llc. The reduction is 9.76% according to 2018Q2 Securities and Exchange form. The company’s stock sank 21.40% while Matarin Capital Management Llc sold 21,804 shares. The health care company reported $23.38B value for the 2018Q2. Now the institutional investor is holding 201,703 shares, compared to the 223,507 from the previous quarter. $1.42 billion is the market cap of Enanta Pharmaceuticals Inc.. The stock decreased 1.91% or $1.42 during the last trading session, reaching $73.03.Enanta Pharmaceuticals, Inc. has 351,022 shares volume, 27.78% up from normal. ENTA is uptrending and has moved 110.33% since December 8, 2017. ENTA outperformed the S&P500 by 94.71%.

Matarin Capital Management Llc operates about $198.00 million and $1382.93 billion US Long portfolio. Its stake in Tcf Financial Corporation (NYSE:TCB) was rose by 29,673 shares to 420,742 shares valued at $10.36B in 2018Q2, according to the filing. Matarin Capital Management Llc has risen its stake in Pc Connection Inc. (NASDAQ:PCCC) and also increased its holding in Idt Corporation Class B (NYSE:IDT) by 12,933 shares in the quarter, for a total of 53,556 shares.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)’s earnings release is expected by WallStreet on February, 6, according to Zacks. Analysts forecast $1.64 EPS, which is $0.86 up or 110.26 % from 2017’s $0.78 EPS. If the current EPS of $1.64 is accurate, ENTA’s profit could be $31.87 million. After $1.30 EPS report previous quarter, Wall Street now predicts 26.15 % EPS growth of Enanta Pharmaceuticals, Inc..

For more Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news brought out recently go to: Nasdaq.com, Seekingalpha.com, Benzinga.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “Why Enanta Pharmaceuticals (ENTA) Could Shock the Market Soon – Nasdaq” brought out on June 01, 2018, “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” on May 08, 2018, “Earnings Scheduled For November 26, 2018 – Benzinga” with a publish date: November 26, 2018, “Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings (Nov. 25-Dec. 1) – Benzinga” and the last “Enanta launches mid-stage study on RSV candidate EDP-938; shares up 4% premarket – Seeking Alpha” with publication date: October 23, 2018.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.